Celgene Corp (CELG.OQ)
86.27USD
18 Jan 2019
$-0.32 (-0.37%)
$86.59
$86.99
$86.99
$85.87
3,970,311
2,574,128
$106.67
$58.61
Fri, Jan 4 2019
Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal
Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.
Celgene, Bristol-Myers set $2.2 bln termination fee for their mega deal
Jan 4 Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.
BRIEF-Ribon Therapeutics Raises $65 Mln
* RIBON THERAPEUTICS - RAISED $65 MILLION IN FINANCING LED BY NOVARTIS VENTURE FUND, WITH JOHNSON & JOHNSON INNOVATION - JJDC, CELGENE, EXISTING INVESTORS
Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever. | Video
UPDATE 7-Bristol-Myers to buy Celgene for $74 bln in largest biopharma deal
Jan 3 Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever.
Grant & Eisenhofer settles fee fight with Celgene whistleblower
The law firm Grant & Eisenhofer has agreed to settle a lawsuit it filed in 2017 in a bid to obtain a cut of the $78 million that a former whistleblower client was awarded for her role in securing a $280 million settlement with drugmaker Celgene Corp.
Father and son advised on opposite sides of Bristol-Celgene deal
For most U.S. families, the holidays are all about gathering around the fireplace, overeating at festive dinners, and playing the occasional board game. But this year, a father and son were also working on the biggest pharmaceutical acquisition of all time.
Father and son advised on opposite sides of Bristol-Celgene deal
Jan 3 For most U.S. families, the holidays are all about gathering around the fireplace, overeating at festive dinners, and playing the occasional board game. But this year, a father and son were also working on the biggest pharmaceutical acquisition of all time.
Cost to insure Bristol-Myers debt jumps as leverage balloons
NEW YORK The cost to insure Bristol-Myers Squibb debt hit its highest point since May 2010 on Thursday, following the announcement that the U.S. pharmaceutical company would acquire rival Celgene Corp in a deal worth about $74 billion.
UPDATE 1-Cost to insure Bristol-Myers debt jumps as leverage balloons
NEW YORK, Jan 3 The cost to insure Bristol-Myers Squibb debt hit its highest point since May 2010 on Thursday, following the announcement that the U.S. pharmaceutical company would acquire rival Celgene Corp in a deal worth about $74 billion.